Amphastar Pharmaceuticals Inc (AMPH) concluded trading on Wednesday at a closing price of $25.34, with 0.39 million shares of worth about $9.98 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.01% during that period and on June 18, 2025 the price saw a loss of about -1.05%. Currently the company’s common shares owned by public are about 47.67M shares, out of which, 34.78M shares are available for trading.
Stock saw a price change of -2.73% in past 5 days and over the past one month there was a price change of 2.22%. Year-to-date (YTD), AMPH shares are showing a performance of -31.75% which decreased to -37.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $22.64 but also hit the highest price of $53.96 during that period. The average intraday trading volume for Amphastar Pharmaceuticals Inc shares is 580.84K. The stock is currently trading -1.11% below its 20-day simple moving average (SMA20), while that difference is up 2.42% for SMA50 and it goes to -29.71% lower than SMA200.
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) currently have 47.67M outstanding shares and institutions hold larger chunk of about 72.37% of that.
The stock has a current market capitalization of $1.19B and its 3Y-monthly beta is at 0.76. PE ratio of stock for trailing 12 months is 9.20, while it has posted earnings per share of $2.76 in the same period. It has Quick Ratio of 2.02 while making debt-to-equity ratio of 0.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMPH, volatility over the week remained 1.25% while standing at 2.03% over the month.
Stock’s fiscal year EPS is expected to drop by -19.13% while it is estimated to increase by 12.49% in next year. EPS is likely to shrink at an annualized rate of -1.31% for next 5-years, compared to annual growth of 25.59% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on May 12, 2025 offering a Neutral rating for the stock and assigned a target price of $30 to it. Coverage by Piper Sandler stated Amphastar Pharmaceuticals Inc (AMPH) stock as a Neutral in their note to investors on February 04, 2025, suggesting a price target of $36 for the stock. On November 22, 2024, Wells Fargo Initiated their recommendations, while on March 05, 2024, JP Morgan Initiated their ratings for the stock with a price target of $60. Stock get a Neutral rating from BofA Securities on November 17, 2023.
